Swiss HLG Winter Conference, Flüeli-Ranft
Pharmaceuticals are in transition. While pharmaceutical companies used to count on blockbusters, part of their strategy today is within rare diseases. In combination with breakthrough innovations for high prevalence diseases, pharmaceutical innovation challenges our reimbursement systems. In a time of dwindling resources, how can a health system guarantee access to innovation and at the same time be affordable? Pharmaceutical innovation not only requires a review of reimbursed pharmaceuticals, but also requires innovation within the entire health care system.